Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq

Roche (RHHBY) announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab). The SC formulation was approved under the brand name Tecentriq Hybreza (atezolizumab and hyaluronidasetqjs). Per Roche, the approval makes Tecentriq Hybreza the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy in the United States. Image Source: Zacks Investment Research Year to date, Roche's shares have gained 8% compared with the industry's 25.4% ...